Wet macular degeneration
Drug research and approvals for wet macular degeneration: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 31 studies of wet macular degeneration are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and the EU has 25 authorised medicines for it.
- Recruiting worldwide: 31
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 25
- A Phase 2 Study of NT-101 Topical in Patients With Wet AMDNCT07811726 · Phase 2 · NexThera Co., Ltd. · starts Jun 11, 2026
- Phase II Study of Subretinal JWK001 for Neovascular Age-Related Macular DegenerationNCT07776522 · Phase 2 · West China Hospital · starts Aug 31, 2026
- Safety and Efficacy Evaluation of SMZ1 With Ranibizumab in Patients With Neovascular Age-related Macular Degeneration…NCT07695207 · Phase 3 · SANGMYUNG innovation · starts Sep 15, 2025
- Ixoberogene Soroparvovec (Ixo-vec) Contralateral Dosing Study in Participants With Neovascular Age-related Macular…NCT07630649 · Phase 2 · Adverum Biotechnologies, Inc. · starts Jun 2, 2026
- Phase 1b/2a Study of EYC-0305 in Patients With Neovascular Age-related Macular DegenerationNCT07587515 · Phase 1 / Phase 2 · Eyconis INC. · starts May 19, 2026
- Safety and Efficacy of AIV007 Periocular Injection in Patients With Neovascular Age-Related Macular DegenerationNCT07557121 · Phase 2 · AiViva BioPharma, Inc. · starts Jul 1, 2026
- A Study of PRL3-zumab in Neovascular Age-related Macular Degeneration (nAMD)NCT07547228 · Phase 1 / Phase 2 · Intra-IMMUSG Pte Ltd · starts Oct 11, 2025
- A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)NCT07496567 · Phase 2 / Phase 3 · EyeBiotech Ltd. · starts Apr 15, 2026
- Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular…NCT07482176 · Phase 3 · Adverum Biotechnologies, Inc. · starts Mar 16, 2026
Approved 7
- RanibizumabVascular endothelial growth factor A inhibitor
- AfliberceptVascular endothelial growth factor A inhibitor
- FaricimabAngiopoietin-2 inhibitor
- Pegaptanib sodiumVascular endothelial growth factor A antagonist
- BrolucizumabVascular endothelial growth factor A inhibitor
- VerteporfinDNA inhibitor
- Bevacizumab gammaVascular endothelial growth factor A binding agent
Phase 3 1
- BevacizumabVascular endothelial growth factor A inhibitor
Phase 2 8
- DorzolamideCarbonic anhydrase II inhibitor
- TimololBeta-1 adrenergic receptor antagonist
- DexamethasoneGlucocorticoid receptor agonist
- Triamcinolone acetonideGlucocorticoid receptor agonist
- TriamcinoloneGlucocorticoid receptor agonist
- ConberceptVascular endothelial growth factor A inhibitor
- TesidolumabComplement C5 binding agent
- Tarcocimab tedromer
Phase 1 or earlier 9
- Abicipar pegolVascular endothelial growth factor A inhibitor
- Retinol
- Lazucirnon
- Tinlarebant
- Ixoberogene soroparvovec
- Gilretinol acetate
- Tarcocimab
- Tedromer
- Migaldendranib
How its trials ended
260 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 63 whose ending is known, 54% met their primary endpoint, 0% missed it and 46% stopped early.
- Completed, result not reported12046%
- Ongoing5320%
- Met its primary endpoint3413%
- Status unknown249%
- Stopped: other or unclear156%
- Stopped: lack of efficacy52%
- Stopped: sponsor or business decision52%
- Stopped: safety21%
- Stopped: enrollment or feasibility21%
| Sep 18, 2026 | SusvimoRanibizumab | Roche Registration GmbH | EMA ↗ |
| Jul 15, 2026 | VislyfaRanibizumab · biosimilar | Lupin Europe GmbH | EMA ↗ |
| Jun 19, 2026 | RexatiluxRanibizumab · biosimilar | Intas Third Party Sales 2005 S.L. | EMA ↗ |
| Feb 10, 2026 | RanluspecRanibizumab · biosimilar | Lupin Europe GmbH | EMA ↗ |
| Sep 15, 2025 | EyluxviAflibercept · biosimilar | Biolitec pharma Limited Zweigniederlassung Jena | EMA ↗ |
| Aug 18, 2025 | MynzepliAflibercept · biosimilar | Advanz Pharma Limited | EMA ↗ |
| Aug 18, 2025 | AfivegAflibercept · biosimilar | STADA Arzneimittel AG | EMA ↗ |
| Aug 14, 2025 | VgenfliAflibercept · biosimilar | Zaklady FarmaFarmaceutyczne Polpharma S.Aceutyczne Polpharma S.A. | EMA ↗ |
| Aug 14, 2025 | EiyzeyAflibercept · biosimilar | Zaklady FarmaFarmaceutyczne Polpharma S.Aceutyczne Polpharma S.A. | EMA ↗ |
| Feb 12, 2025 | EydenzeltAflibercept · biosimilar | Celltrion Healthcare Hungary Kft. | EMA ↗ |
| Jan 13, 2025 | AhzantiveAflibercept · biosimilar | Formycon AG | EMA ↗ |
| Jan 13, 2025 | BaiamaAflibercept · biosimilar | Formycon AG | EMA ↗ |
| Nov 13, 2024 | AfqlirAflibercept · biosimilar | Sandoz GmbH | EMA ↗ |
| Nov 13, 2024 | OpuvizAflibercept · biosimilar | Samsung Bioepis NL B.V. | EMA ↗ |
| Sep 19, 2024 | Epruvy (previously Ranibizumab Midas)Ranibizumab · biosimilar | Midas Pharma GmbH | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA